Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus

被引:0
|
作者
Chang, Li-Hsin [3 ]
Chu, Chia-Huei [4 ,5 ]
Huang, Chin-Chou [6 ]
Lin, Liang-Yu [1 ,2 ]
机构
[1] Taipei Vet Gen Hosp, Dept Med, Div Endocrinol & Metab, 201 Sec 2,Shih Pai Rd, Taipei 11217, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Fac Med, Taipei, Taiwan
[3] Yeezen Gen Hosp, Dept Med, Div Endocrinol & Metab, Taoyuan, Taiwan
[4] Mackay Mem Hosp, Dept Otorhinolaryngol Head & Neck Surg, Taipei, Taiwan
[5] MacKay Med Coll, Dept Audiol & Speech Language Pathol, New Taipei City, Taiwan
[6] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan
关键词
macrovascular complications; microvascular complications; soluble tumor necrosis factor receptor type 1; type 2 diabetes mellitus; MICROVASCULAR DISEASE; FUNCTION DECLINE; KIDNEY-DISEASE; BIOMARKERS; METAANALYSIS; ALBUMINURIA; PROGRESSION; PEOPLE; RISKS; ALPHA;
D O I
10.1177/20420188231207345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Inflammations are the crucial pathogenesis of chronic complications of type 2 diabetes mellitus (T2DM).Objectives: The timeline of cardiovascular and renal complications of T2DM and whether soluble tumor necrosis factor receptor type 1 (sTNFR1) levels predict cardiorenal outcomes were still elusive.Design: Prospectively observational study.Methods: Chinese patients with T2DM were enrolled. Cardiorenal composite events defined by either cardiovascular composite events (all-cause mortality, acute coronary syndrome, or non-fatal stroke) or renal composite events (a decline of >30% of renal function or worsening status of albuminuria) were followed. Associations of sTNFR1 levels and cardiovascular, renal, and cardiorenal composite events were analyzed in regression models presented by hazard ratio (HR) and 95% confidence interval (95% CI).Results: Among 370 subjects, 42 cardiovascular and 86 renal composite events occurred. Higher sTNFR1 levels were related to higher frequency and risks of cardiovascular composite events (HR 1.07, 95% CI 1.01-1.13, p = 0.009) and renal composite events (HR 1.05, 95% CI 1.02-1.09, p < 0.001). Occurrences of cardiovascular composite events were not predicted by precedential renal composite events. sTNFR1 levels were proved to be associated with risks of cardiorenal composite events in Cox regression sequential models (adjusted HR 1.04, 95% CI 1.00-1.08, p = 0.03). The results were consistent in all subgroup analyses.Conclusion: Levels of sTNFR1 were associated with cardiorenal complications of T2DM and the predictabilities of TNFR1 levels were better than precedential cardiovascular or renal events.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus
    Chang, L. -H.
    Hwu, C. -M.
    Chu, C. -H.
    Lin, Y. -C.
    Huang, C. -C.
    You, J. -Y.
    Chen, H. -S.
    Lin, L. -Y.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (12) : 2609 - 2619
  • [2] The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus
    L.-H. Chang
    C.-M. Hwu
    C.-H. Chu
    Y.-C. Lin
    C.-C. Huang
    J.-Y. You
    H.-S. Chen
    L.-Y. Lin
    Journal of Endocrinological Investigation, 2021, 44 : 2609 - 2619
  • [3] SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TYPE 1 LEVELS EXHIBIT A STRONGER ASSOCIATION WITH RENAL OUTCOMES THAN TRADITIONAL RISK FACTORS IN CHINESE SUBJECTS WITH TYPE 2 DIABETES MELLITUS
    Chang, Li-Hsin
    Hwu, Chii-Min
    Lin, Yi-Chun
    Huang, Chin-Chou
    Won, Justin G. S.
    Chen, Harn-Shen
    Lin, Liang-Yu
    ENDOCRINE PRACTICE, 2020, 26 (10) : 1115 - 1124
  • [4] Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
    Gerstein, Hertzel C.
    Sattar, Naveed
    Rosenstock, Julio
    Ramasundarahettige, Chinthanie
    Pratley, Richard
    Lopes, Renato D.
    Lam, Carolyn S. P.
    Khurmi, Nardev S.
    Heenan, Laura
    Del Prato, Stefano
    Dyal, Leanne
    Branch, Kelley
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10): : 896 - 907
  • [5] Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
    Williams, David M.
    Nawaz, Asif
    Evans, Marc
    DIABETES THERAPY, 2020, 11 (02) : 369 - 386
  • [6] Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
    David M. Williams
    Asif Nawaz
    Marc Evans
    Diabetes Therapy, 2020, 11 : 369 - 386
  • [7] International Variability of Renal and Cardiovascular Outcomes and Mortality in Patients with Type 2 Diabetes Mellitus in Europe
    Thoeni, Stefanie
    Keller, Felix
    Denicolo, Sara
    Eder, Susanne
    Buchwinkler, Lukas
    Rosivall, Laszlo
    Wiecek, Andrzej
    Mark, Patrick Barry
    Rossing, Peter
    Heerspink, Hiddo L.
    Mayer, Gert
    KIDNEY & BLOOD PRESSURE RESEARCH, 2023, 48 (01): : 165 - 174
  • [8] Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes
    Libianto, Renata
    Davis, Timothy M. E.
    Ekinci, Elif I.
    MEDICAL JOURNAL OF AUSTRALIA, 2020, 212 (03) : 133 - 139
  • [10] Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes
    Axel C. Carlsson
    Carl Johan Östgren
    Fredrik H. Nystrom
    Toste Länne
    Pär Jennersjö
    Anders Larsson
    Johan Ärnlöv
    Cardiovascular Diabetology, 15